Is CorMedix, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its valuation outlook. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests that the stock is trading at a lower price relative to its growth potential. Additionally, the P/E ratio stands at 55, which, while high, is offset by a robust ROCE of 38.54%, indicating efficient capital use.
In comparison to peers, CorMedix's valuation metrics are compelling; for instance, Xeris Biopharma Holdings, Inc. has a significantly negative P/E of -38.70, highlighting the relative strength of CorMedix. Furthermore, the EV to EBITDA ratio of 57.92 also contrasts sharply with the peer average, reinforcing the attractiveness of CorMedix's valuation. Despite recent underperformance in the short term, with a 1-week return of -5.13% compared to the S&P 500's 1.70%, the company's long-term performance over three years shows a remarkable return of 229.45%, significantly outpacing the index.